Beyond the Drug: What Makes TACE Work?

Show notes

This episode breaks down PRECISION V, the 2010 randomized trial that helped make drug-eluting beads a standard option for hepatocellular carcinoma (HCC), and tests its conclusions against later bland-bead and anatomy data. Following, there is an expert commentary by Dr. Premal Trivedi, Chief of Interventional Radiology at the University of Colorado.

• The Premise: Conventional TACE uses an unstable lipiodol emulsion that leaks doxorubicin into the systemic circulation. Drug-eluting beads promised to hold the drug in the tumor and block flow permanently.
• Efficacy: In about 200 BCLC A/B patients, six-month objective response was 51.6% with DC Bead versus 43.5% with conventional TACE (p = 0.11), so the trial missed its primary endpoint. A post hoc advanced-disease subgroup favored the beads (52.4% versus 34.7%).
• Toxicity: Bead patients received more doxorubicin but had far less alopecia (1.1% versus 20.4%), lower peak ALT and preserved LVEF. Post-embolization syndrome was nearly identical.
• The Catch: The MSKCC Brown trial compared doxorubicin-loaded beads with bland beads and found essentially the same response and survival, which suggests ischemia, not the drug, is doing the work.
• Caveats: The trial was an industry-sponsored phase II study with six months of follow-up and no survival endpoints. It was underpowered once the control arm outperformed expectations.
• Expert Take: Dr. Trivedi notes that systemic doxorubicin alone yields only about a 10% response in HCC, and that most of TACE's benefit comes from the depth and completeness of ischemia.

Tune in to learn why the embolization, not the chemotherapy, may be doing the heavy lifting in TACE.

This podcast is generated using an AI model that has been trained in the context of endovascular surgery and interventional radiology in addition context of the article cited below. The content was reviewed and edited by multiple healthcare professionals in the field.

Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41-52.